{"id":"W4323652772","doi":"10.1007/s00280-023-04516-9","title":"A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"Pfizer","keywords":"Gemtuzumab ozogamicin; Medicine; Dosing; Calicheamicin; Refractory (planetary science); Pharmacokinetics; CD33; Myeloid leukemia; Internal medicine; Oncology; Pharmacology; CD34; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006369952,0.0003101474,0.0006783137,0.0004261611,0.0001433757,0.00001526632,0.000118459,0.0001407865,0.0002694082],"category_scores_gemma":[0.00003013619,0.0002724214,0.00006515681,0.000722391,0.0002060681,0.0001991255,0.00009702694,0.0007431939,0.000002522408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001040266,"about_ca_system_score_gemma":0.0005006518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002537337,"about_ca_topic_score_gemma":0.00001614028,"domain_scores_codex":[0.9977604,0.0002827359,0.000513109,0.0005817287,0.0003866163,0.0004754221],"domain_scores_gemma":[0.9988847,0.0003437168,0.0002250544,0.0001562173,0.0002190025,0.0001712725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.05238259,0.002061114,0.1709447,0.0002930478,0.003832646,0.0002911972,0.01113956,0.00020329,0.6062787,0.000001495921,0.001814873,0.1507568],"study_design_scores_gemma":[0.3989805,0.02128388,0.387436,0.0008903982,0.002441402,0.0000411539,0.002740746,0.03047077,0.1528406,0.00002647609,0.001837209,0.001010787],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963706,0.0005807583,0.00003355102,0.0005689642,0.0003601691,0.001879887,0.00006446756,0.00006561801,0.00007598141],"genre_scores_gemma":[0.9961354,0.00210263,0.0001397609,0.001019063,0.0001607005,0.000123641,0.00008155621,0.00006981162,0.0001674182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.453438,"threshold_uncertainty_score":0.9999728,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02479243153748407,"score_gpt":0.386802173481273,"score_spread":0.3620097419437889,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}